Page 5,519«..1020..5,5185,5195,5205,521..5,5305,540..»

Certified stroke centers more likely to give clot-busting drugs

Posted: Published on March 27th, 2013

Mar. 26, 2013 Stroke patients are three times more likely to receive clot-busting medication if treated at a certified stroke center, according to a study in the Journal of the American Heart Association. Intravenous tissue plasminogen activator (tPA) is the only drug approved by the Food and Drug Administration for emergency treatment for people who have ischemic (clot-caused) stroke. The durg can reduce stroke disability. "The stroke center concept has rapidly taken off, and this data demonstrates one way that certified centers are doing better than non-certified centers," said Michael T. Mullen, M.D., the study's lead author and an assistant professor of neurology at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. The researchers examined hospital discharge data on 323,228 ischemic stroke patients from 26 states in 2004-09. The clot-buster was administered to: After researchers adjusted for patient and facility characteristics, they found the likelihood of receiving tPA was still almost twice as high in certified stroke centers. Over time, tPA use increased from 6 percent to 7.6 percent at certified primary stroke centers and 1.4 percent to 3.3 percent at non-certified hospitals. During a stroke, blood flow must be restored quickly and tPA can only … Continue reading →

Comments Off on Certified stroke centers more likely to give clot-busting drugs

Acute stroke therapy used 3 times more at certified primary stroke centers

Posted: Published on March 27th, 2013

Public release date: 26-Mar-2013 [ | E-mail | Share ] Contact: Kim Menard kim.menard@uphs.upenn.edu 215-662-6183 University of Pennsylvania School of Medicine PHILADELPHIA - Certified Primary Stroke Centers are three times more likely to administer clot-busting treatment for strokes than non-certified centers, reports a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania. The study, published in the Journal of the American Heart Association, looked at a wide sample of hospitals across the United States, and provides insight into practice across the US health care system as experts examine ways to increase the use of this important therapy. Clot busting treatment is used to open blocked blood vessels, restoring blood flow to the brain and reducing disability after stroke. Less than half of ischemic stroke patients who are eligible for the treatment, recombinant tissue plasminogen activator (rt-PA), actually receive it. Currently, only a small percentage of stroke patients receive rt-PA therapy. "We found that primary stroke centers administered rt-PA at a much higher rate than other hospitals, demonstrating one way that certified centers are succeeding." said Michael T. Mullen, MD, the study's lead author and an assistant professor of Neurology at the Perelman School of … Continue reading →

Comments Off on Acute stroke therapy used 3 times more at certified primary stroke centers

Better treatment for stroke patients on horizon

Posted: Published on March 27th, 2013

Public release date: 26-Mar-2013 [ | E-mail | Share ] Contact: Emily Walker emily.walker@monash.edu 61-399-034-844 Monash University Two molecules may provide, for the first time, an indication of which stroke patients will suffer a further, long-term neurological deficit, allowing doctors to tailor treatment more effectively. Subarachnoid haemorrhage (SAH), a form of stroke, affects around half a million people worldwide each year. Nearly 50 per cent of patients who survive the initial haemorrhage die within 30 days, with survivors likely to suffer permanent disability. A study by Dr Sanjaya Kuruppu and Professor Ian Smith of Monash University and clinicians at Harvard Medical School, Dr Mingming Ning and Dr Sherry Chou, has shown that there may be a way to predict the sub-group of SAH patients that will suffer severe long-term disability. By assessing the cerebrospinal fluid of SAH patients, the researchers discovered that in the three days immediately following the stroke, an enzyme, endothelin converting enzyme-1 (ECE-1) and its substrate big endothelin-1 (BigET-1) were elevated in patients that suffered a disability that severely impacted on their capacity to self-care. Dr Sanjaya Kuruppu, of the Monash Department of Biochemistry and Molecular Biology said the discovery was a breakthrough in treating a deadly … Continue reading →

Comments Off on Better treatment for stroke patients on horizon

The peripheral nervous system can often heal itself from injuries

Posted: Published on March 27th, 2013

The central nervous system includes the brain and spinal cord. The peripheral nervous system is comprised of all the nerve branches that leave the skull or spine to feed the individual muscles and areas of sensation. The most dramatic difference between the two systems is that, unlike the peripheral nerves, once the human brain or spinal cord is injured, they are essentially incapable of significant regeneration. Damage for the most part is permanent, and this limitation is consistent for all mammals, not just for humans. Scientists continue to study ways to change this natural boundary hoping to someday stimulate the spinal cord or brain to repair itself, but the inroads have been small. The peripheral nerves, however, have been given the miraculous capability to regenerate and repair themselves. The process of how a nerve dies back after injury, and then begins the process of repair, has been studied in detail since the first experiments by Augustus Waller in 1951. Waller was a British physician who made his discoveries through detailed studies on frogs, identifying the first steps that occur when a nerve is injured. The process remains well known today among scientists as Wallerian degeneration. Once a peripheral nerve injury … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on The peripheral nervous system can often heal itself from injuries

Pinning down the pain: Schwann cell protein plays major role in neuropathic pain

Posted: Published on March 27th, 2013

Mar. 27, 2013 An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, says a key protein in Schwann cells performs a critical, perhaps overarching, role in regulating the recovery of peripheral nerves after injury. The discovery has implications for improving the treatment of neuropathic pain, a complex and largely mysterious form of chronic pain that afflicts over 100 million Americans. The findings are published in the March 27, 2013 issue of the Journal of Neuroscience. Neuropathic pain occurs when peripheral nerve fibers (those outside of the brain and spinal cord) are damaged or dysfunctional, resulting in incorrect signals sent to the brain. Perceived pain sensations are frequently likened to ongoing burning, coldness or "pins and needles." The phenomenon also involves changes to nerve function at both the injury site and surrounding tissues. Not surprisingly, much of the effort to explain the causes and mechanisms of neuropathic pain has focused upon peripheral nerve cells themselves. The new study by principal investigator Wendy Campana, PhD, associate professor in UC San Diego's Department of Anesthesiology, with colleagues at UC San Diego and in Japan, Italy and New York, points to a surprisingly critical role … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Pinning down the pain: Schwann cell protein plays major role in neuropathic pain

Case 1 – Video

Posted: Published on March 27th, 2013

Case 1主要說明golf彈出原因是因為入射角和速度問題. By: DAVIDCHOI1224 … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Case 1 – Video

Neurodegenerative Diseases Market: Analysis & Forecast 2018 in News Research Report at ReportsnReports.com

Posted: Published on March 27th, 2013

Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinsons disease treatment will boost market despite patent cliff and Neurodegenerative Diseases Pipeline Review, H1 2013 are new research reports available at ReportsnReports.com store. Dallas, Texas (PRWEB) March 27, 2013 Scope Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=229830. Reasons to Buy Neurodegenerative Diseases Pipeline Review, H1 2013 (http://www.reportsnreports.com/reports/228409-neurodegenerative-diseases-pipeline-review-h1-2013.html) provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Neurodegenerative Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neurodegenerative Diseases. Neurodegenerative Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, and investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope Reasons to buy Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=228409. Continued here: Neurodegenerative Diseases Market: Analysis & Forecast 2018 in News Research Report at … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Neurodegenerative Diseases Market: Analysis & Forecast 2018 in News Research Report at ReportsnReports.com

Ashland group prepares for Parkinson ‘s awareness month

Posted: Published on March 27th, 2013

A local group is increasing its outreach starting next month to better educate people on the effects of Parkinson's disease. The Ashland Parkinson's Support Group will have two displays set up at the community center and the public library in April for Parkinson's Awareness Month. "We want to share that this is a serious disease that needs energy put into it to find a cause and a cure," said Martha Budding, the group's coordinator. The displays will include posters, fliers and facts about Parkinson's, a degenerative movement disorder. According to the Parkinson's Disease Foundation, as many as 60,000 Americans are diagnosed with Parkinson's annually. Founded a year and a half ago, the Parkinson's Support Group meets once a month at the community center. Speakers present different Parkinson's-related topics, such as treatment and resources. As many as 20 people attend the monthly presentations, and the group also hosts two exercise programs a week for people with Parkinson's. "We are beginning to see the benefits of the exercises and the topics we have," Budding said. "We are learning more and we are more empowered than we were before." Local resident Malcolm Smart is putting the library display together, which Library Director Paula … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Ashland group prepares for Parkinson ‘s awareness month

Amarantus BioScience Reports Positive MANF Data in Neuroprotection Animal Models of Parkinson ’s Disease

Posted: Published on March 27th, 2013

SUNNYVALE, Calif.--(BUSINESS WIRE)-- Amarantus BioScience, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today reported positive preclinical data for its lead therapeutic MANF in neuroprotection 6-hydroxydopamine (6-OHDA) rat models of Parkinsons disease. The data show that MANF protects the integrity of dopamine producing neurites in the striatum. Our scientists are excited by this data, which not only demonstrates the efficacy of MANF, but its superiority to GDNF, as well, said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience. Based on this study, we believe MANF plays a role in maintaining brain connectivity, specifically the dopaminergic system of the basal ganglia network, which reinforces the potential of MANF as a disease-modifying treatment for Parkinsons. In the neuroprotection study, MANF was delivered into the substantia nigra shortly before injection of the toxin 6-OHDA into the striatum. Four weeks later the animals were sacrificed and the density of dopaminergic neuron projections in the striatum was determined. The protection of neuron health, as measured by the density of neurite terminals, was evident in all three areas of the striatum examined. The effects of a single MANF treatment were evident after four … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Amarantus BioScience Reports Positive MANF Data in Neuroprotection Animal Models of Parkinson ’s Disease

Neurodegenerative Diseases Market to 2018 – New product entries in both niche and broader Parkinson ‘s disease …

Posted: Published on March 27th, 2013

NEW YORK, March 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff http://www.reportlinker.com/p01154050/Neurodegenerative-Diseases-Market-to-2018---New-product-entries-in-both-niche-and-broader-Parkinson's-disease-treatment-will-boost-market-despite-patent-cliff.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff Summary - The current therapeutic environment in the treatment of AD, PD, HD and ALS across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan. - Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations. - Market forecasts for all four indications across the US, the top five countries in Europe (EU5) - Germany, France, the UK, Italy, and Spain- as well as Japan. - Key market drivers and barriers - The major deals that have taken place in the Neurodegenerative Diseases Market in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Neurodegenerative Diseases Market to 2018 – New product entries in both niche and broader Parkinson ‘s disease …

Page 5,519«..1020..5,5185,5195,5205,521..5,5305,540..»